HNO210 Cells

The HNO210 cell line is derived from a laryngeal squamous cell carcinoma, a subtype of head and neck squamous cell carcinoma (HNSCC). This cell line has been extensively characterized for its genetic and molecular features, making it a valuable model for studying the pathogenesis and treatment responses of HNSCC. Chromosomal comparative genomic hybridization (cCGH) analysis of HNO210 has revealed several significant chromosomal aberrations. Notably, it exhibits DNA copy number gains in chromosomal regions 3q, 7p, 7q, 9p, 9q, 20p, and 20q, and copy number losses in 3p, 4p, 4q, and chromosome 21. These genetic alterations are common in HNSCC and are associated with aggressive tumor behavior and poor patient prognosis. In particular, the amplification of regions such as 3q and 11q13, which is seen in many HNSCC cell lines, is of interest due to its correlation with increased expression of oncogenes such as CCND1 (cyclin D1) and CTTN (cortactin). These genes are involved in cell cycle regulation and cytoskeletal organization, respectively, and their overexpression can contribute to enhanced cell proliferation, invasion, and metastasis. The HNO210 cell line, with its distinct genetic profile, serves as a robust model for investigating the molecular mechanisms underlying laryngeal cancer progression and for testing targeted therapies that address these specific genetic abnormalities. Additionally, this cell line is part of a panel used to explore the efficacy of combination therapies, such as the use of cisplatin with thalidomide, which have shown promise in enhancing anti-tumor activity in vitro and in vivo. This makes HNO210 not only crucial for basic cancer research but also for translational studies aimed at improving therapeutic outcomes for patients with HNSCC.